• Emergency uses of the vaccine have not been approved or licensed by the FDA, but have been authorized by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19). The Moderna COVID-19 Vaccine is authorized in individuals 6 months of age and older as a primary series. The Moderna COVID-19 Vaccine, Bivalent is authorized as a booster dose in individuals 6 years of age and older.

  • The EUA for these products is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner.

  • For more information on the EUA authorized uses of the vaccine, refer to the Fact Sheets for Healthcare Providers Administering Vaccine (Vaccine Providers) and Full Prescribing Information.

Sign up to receive updates from Moderna

Current Clinical Trials

Here are some of the clinical trial programs that are currently investigating Moderna COVID-19 Vaccine.

Study 6: Bivalent Booster Dose

Study 6 is a Phase 2/3 open-label study to evaluate the immunogenicity, safety, and reactogenicity of Moderna COVID-19 Vaccine, Bivalent in participants 18 years of age and older.

Phase 2/3 Trial (NCT04927065)

Study 1: Primary Series

Study 1 is an ongoing Phase 3 randomized, placebo-controlled, observer-blind clinical trial to evaluate the efficacy, safety, and immunogenicity of the Moderna COVID-19 Vaccine in participants 18 years of age and older in the United States.

Other Primary Series Studies

Phase 1 Trial, Study P101 (NCT04283461)